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INTRODUCTION
In December 2019, the first, troublesome news con-
cerning a novel and highly infective viral pneumonia spreading 
from Wuhan (China) came to our attention.1 It was difficult at 
that time to predict, let alone imagine, the magnitude of how se-
vere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
would change the way we practice medicine (not to mention 
our lives) only 2 months later. The first report on February 20 
of a severe case of coronavirus disease 19 (CoViD-19) in a fit, 
young male from Codogno, a town just south of Milan, was 
rapidly followed by the identification of clusters of infected 
patients in the densely populated Lombardia region (approxi-
mately 10 million inhabitants with a density of 421.6 inhabit-
ants/sq km) and in nearby regions within Northern Italy.2
Our hospital, Policlinico San Donato Research Hospital, 
is a university hospital located in the southeastern part of the 
Milan metropolitan area, where it represents one of the lar-
gest clinics in the territory. Our daily activity as gastroenter-
ologists was immediately affected. We promptly implemented 
a strategy of phone call screenings before any gastrointestinal 
(GI) consults or endoscopic procedures, questioning patients 
about their geographic provenance (prohibiting patients from 
coming from the so-called red zone, the area surrounding 
Codogno), suspicious symptoms, and high-risk contacts. We 
had just started to contemplate how to safely continue our en-
doscopic activities in the absence of clear indications regarding 
the use of personal protective equipment (PPE) when within 
a few days the regional health system was overwhelmed by a 
massive number of CoViD-19 patients. Lombardia rapidly be-
came one of the most severely affected regions of the world, 
with 54,802 infected individuals, identified by performing 
176,953 nasopharyngeal swabs, and 10,022 deaths by April 9.3 
On March 8, the entire region was declared a red zone, and 
2 days later a complete national lockdown was declared.
Within the entire national territory, all nonurgent con-
sults and procedures were cancelled and indefinitely post-
poned. With routine activities halted, all gastroenterologists 
from our GI unit except one have been reassigned to provide 
care to CoViD-19 patients. One after another, seven CoViD-19 
units were created and staffed with doctors of various special-
ties to manage >200 dedicated hospital beds. A small internal 
medicine ward, dedicated to care for the few noninfected pa-
tients accessing the hospital for urgent medical conditions, was 
preserved and also used for GI emergencies. In 2 weeks our 
hospital, like many others in Northern Italy, was almost com-
pletely converted into a CoViD-19 hospital. Every possible 
effort was made to quickly increase the capacity of intensive 
care units (ICUs) to accommodate the alarming numbers of 
very sick CoViD-19 patients, including constructing new units 
in unused areas of the hospital or converting surgical rooms 
into ICUs.
These drastic measures were implemented in a very short 
period of time, and although necessary to counteract the dev-
astation brought about by the outbreak, they also posed tre-
mendous challenges to the care of patients with GI conditions, 
including those with inflammatory bowel diseases (IBD). 
Indeed, with severely reduced resources in regard to personnel, 
equipment, and space to manage patients, our IBD center had 
to face several critical issues.
COUNSELING OF PATIENTS WITH IBD
As a tertiary care center for IBD patients and one of 
the most prominent in the Milan metropolitan area, our IBD 
center from the very beginning of the CoViD-19 pandemic 
has been hit with a daily onslaught of phone calls and e-mails 
from our patients with concerns as to how the situation may 
affect them. Many were anxious about the necessity to post-
pone their already planned consults or endoscopies, and others 
were truly terrified of the idea of coming to the hospital for 
scheduled infusions or visits. Most of the questions, however, 
were related to patients’ risk of infection, especially while on 
immunosuppressive therapies.
Indeed, to date, available evidence-based information 
regarding the risk of CoViD-19 infection in IBD is scarce. 
Anecdotally, IBD patients do not appear to be at higher risk 
of developing CoViD-19 compared with the general popula-
tion. In fact, the Chinese Elite IBD Union did not identify any 
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SARS-CoV-2 infected patients in their patient registry,4 and to 
date only a few infected IBD patients have been reported in the 
literature. Nonetheless, although these data are quite encour-
aging, solid epidemiologic evidence from areas with high IBD 
prevalence, such as in Western countries, is lacking at the pre-
sent time and it is unclear whether the observations in China 
can be extrapolated to the rest of the IBD patient population 
worldwide. As such, although it is reasonable to reassure pa-
tients, this does not mean that they can ignore general precau-
tions. Indeed, the single most important intervention we can 
engage in to protect our patients with IBD is to emphasize the 
importance of “primary prevention”: that is, avoiding, as much 
as possible, the risk of getting infected. This is especially true 
in frail patients—specifically, elderly or malnourished patients, 
those with several comorbidities, and those with long-standing 
aggressive disease—who respond poorly to current treatments. 
These particular IBD patients, with the aforementioned con-
ditions, are highly likely to be at significant increased risk of 
severe SARS-CoV-2 infections.
The importance of  hand-washing and other simple 
measures, such as avoiding touching the nose, ears, and eyes 
with dirty hands and covering the mouth and nose with a bent 
elbow when coughing or sneezing, is often underestimated. 
The possibility of  orofecal transmission, suggested by the find-
ings of  viral RNA in stool even after patients have tested neg-
ative by nasopharyngeal swab,5 has to be considered. Routine 
use of  PPE is still a matter of  debate. Although not currently 
recommended by the World Health Organization because of 
the lack of  evidence,6 the use of  masks, even in the absence 
of  symptoms, appears reasonable to us. In any case, the use 
of  PPE (eg, masks and gloves) has rapidly and widely become 
commonplace among the general population. From this per-
spective, our role is also to inform patients how to correctly use 
these PPE devices, because incorrect behavior may paradoxi-
cally increase the risk of  infection: for example, by touching the 
outer side of  the mask, reusing the same mask for several days, 
touching the face with gloves, and removing gloves improperly. 
In addition, the need to comply with social distancing recom-
mendations, avoiding crowded places, and not leaving home 
unless necessary must be stressed as much as possible. It is im-
portant to explain that coming to hospitals for nonurgent pro-
cedures or consultations is an unnecessary risk that should be 
absolutely avoided.
As a matter of fact, while reducing access to hospitals, 
we have had to rely as much as possible on telemedicine. Likely 
similar to most centers in Italy, our center does not use any spe-
cific system or dedicated equipment for this purpose. We have 
tried to do our best to provide adequate service for our IBD pa-
tients, despite the marked reduction of dedicated GI personnel, 
now largely reassigned to CoViD-19 units. We have managed 
to have at least one person (GI- or IBD-dedicated nurse) avail-
able 24/7 to answer e-mails and phone calls. This more “pas-
sive” approach may be adequate for patients with mild, stable 
disease. However, for patients on biologic therapies, we have 
implemented a mandatory phone call-in the day before any 
planned hospital visit to screen for possible CoViD-19 symp-
toms or contact with infected individuals and to reassure pa-
tients that all possible precautions are being taken by the IBD 
center to reduce the risk of infection. Clinical conditions of 
patients on subcutaneous biologics can usually be checked by 
phone call; in addition, whenever possible, we use drug delivery 
services, established by the National Health System, specifically 
to provide hospital-dispensed medications to patients during 
this pandemic.
Of course, in centers with greater numbers of available 
and dedicated personnel, an “active” approach, which means 
reaching out to every patient with IBD to provide instructions 
and reassurance, should be preferred. From this point of view, 
specialized personnel, such as IBD-dedicated nurses, are of 
paramount importance.
MANAGEMENT OF IMMUNOSUPPRESSIVE 
THERAPIES (BIOLOGICS, THIOPURINES, 
STEROIDS)
Despite the fact that data from the SARS and Middle 
East respiratory syndrome coronaviruses did not show a higher 
risk in immunosuppressed patients,7 the impact of immuno-
suppressive therapies on CoViD-19 is largely unknown, and no 
evidence-based recommendations can be provided at this time. 
With only a few cases of infected IBD patients reported, this 
situation is particularly true in our field. Interestingly, however, 
immunosuppressive drugs such as hydroxychloroquine8 and 
tocilizumab9 have been proposed as therapies for CoViD-19. 
Thus, it is possible that targeting the immune system with spe-
cific compounds will reduce the immune-related lung damage 
characteristic of SARS-CoV-2 infection and dampen the se-
verity of the disease. On the other hand, immunosuppressive 
drugs are usually associated with more severe viral infections 
because they may increase viral load.
Undeniably, whereas nonurgent consults and procedures 
in IBD patients with mild disease can safely be postponed, 
those on biologics are at risk of  disease relapse if  ther-
apies are suddenly stopped. Accordingly, the International 
Organization for the Study of  Inflammatory Bowel Disease10 
recommends not stopping biologic therapies, including infu-
sion therapies administered in hospitals, assuming that the 
infusion center provides an adequate screening protocol. We 
agree that in these patients the risk of  causing a disease re-
lapse when interrupting biologic therapies is probably higher 
than the risk of  developing severe CoViD-19 because of  the 
effects of  immunomodulation; however, every effort should be 
made to protect them from the risk of  infection. In hospitals 
where CoViD-19 patients are treated (like ours), the delinea-
tion of  well-defined “clean” pathways is pivotal to minimize 
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medical and nonmedical personnel involved at the infusion 
center should be excluded from the care of  CoViD-19 pa-
tients. Counseling by phone, as addressed before, is of  great 
importance to improve and secure adherence.
For patients being treated using thiopurines, suspension of 
therapy is not recommended, even though these therapies have a 
prolonged effect after their suspension. Combination therapy with 
biologics may be a situation of particular concern, but again there 
are currently no data available to support the suspension of one 
agent in this setting. In our clinical practice we discuss this issue with 
each patient, making decisions on a case-by-case basis, according to 
disease history and patient preferences.
Importantly, the practice of  using corticosteroids for 
the treatment of  IBD is commonplace and widely accepted. 
Whereas a placebo-controlled randomized trial showed that 
corticosteroids may reduce SARS coronavirus clearence,11 
other studies have suggested a possible positive influence of 
these drugs on the SARS outcome because of  their potent 
anti-inflammatory properties.12 Steroids are currently being 
used in our country to treat patients with moderate-to-severe 
CoViD-19, to reduce the signs and symptoms of  “super” (se-
vere) inflammation in the later phases of  the disease. However, 
in the early stages (the viral phase of  infection) they should 
be avoided because their use may increase viral burden. The 
recommendation to reduce as much as possible or discontinue 
systemic steroids in IBD patients given by the International 
Organization for the Study of  Inflammatory Bowel Disease 
appears reasonable, but the decision should be made on an 
individual basis, discussing the benefits and risks with each 
patient. Of  course, steroid tapering (especially if  accelerated) 
should always be conducted under strict medical surveillance, 
possibly with planned follow-up phone calls and, in any case, 
ensuring unlimited availability by phone. Again, primary pre-
vention is the most important recommendation we can give 
to our patients being treated using steroids.
CONDUCTING CLINICAL TRIALS
Another particularly challenging issue we are facing 
during the CoViD-19 outbreak is conducting clinical trials. 
Our center normally handles 10-15 ongoing clinical trials, and 
randomized clinical trials on novel therapeutic compounds 
are an important resource we use in the management of IBD 
patients. However, as many of us know, great efforts are com-
monly required to properly conduct these studies, in com-
pliance with more and more complex protocols. As one may 
expect, advancing study procedures with a significant reduction 
of resources has become quite challenging. Still, it is critical for 
the patients, and for the IBD center, to do whatever is necessary 
to guarantee continuation of the trial(s) by enrolling patients 
and avoiding, as much as possible, protocol deviations. Even 
more so than routine biologic infusions, particular attention 
should be paid to observing clean pathways and the use of PPE 
to avoid potential hospital infections. In addition, the reporting 
of adverse events should be precise and carefully monitored 
to separate potential confounding factors because of the cur-
rent situation. Overall, although we are assuring our patients, 
particularly those who were already enrolled in clinical trials 
at the beginning of the coronavirus emergency, that our intent 
is to continue these studies, at present we are also carefully 
evaluating any new possible enrollments because of the afore-
mentioned difficulties that may impact our ability to properly 
conduct these trials.
MANAGEMENT OF IBD RELAPSES
Not only is providing adequate follow-up for chronic dis-
eases such as IBD complicated during the outbreak, but ensuring 
adequate care of patients with acute conditions is complicated as 
well. As already mentioned, in many hospitals gastroenterologists 
have had to be reassigned and are now directly involved in the care 
of CoViD-19 patients. Even if urgent consults and endoscopic 
procedures are granted (a 24/7 referral service is maintained for 
emergent endoscopies), this reorganization adds further difficul-
ties to the management of patients with acute GI diseases who 
deserve admission. As an example, acute reactivation of IBD 
has other unique features that may further complicate patient 
management. First, coronavirus infection may present with GI 
symptoms, such as diarrhea, weight loss, and abdominal pain, ac-
companied by mild to moderate fever and no (or mild) respiratory 
symptoms.13 As such, CoViD-19 may mimic IBD relapse symp-
toms, adding one more diagnostic challenge to this patient pop-
ulation. Moreover, the intense pressure on the emergency system 
plus patients’ fear of being admitted to an “infected” hospital 
may cause delays in the diagnosis and treatment of acute flares, 
consequently increasing the risk of medical treatment failure and 
the need for urgent surgical intervention (eg, in patients with se-
vere ulcerative colitis). In many hospitals, medical and even sur-
gical units have been converted to CoViD-19 units. As such, even 
if surgeons are still available for urgent cases, another problem 
to take into account is the availability of ICU beds in hospitals 
overwhelmed with CoViD-19 patients. In fact, it is very likely that 
ICUs are completely occupied by critical CoViD-19 patients and 
that there is no room for “clean” patients.
Considering these difficulties, we preventively assigned 
a CoViD-19-free hospital with IBD-dedicated gastroenterol-
ogists and surgeons, where we can promptly transfer any pa-
tients with severe IBD who have a significant risk of needing 
surgery and who may be admitted to our hospital during the 
outbreak. We strongly recommend the creation of such net-
works with surrounding hospitals to select dedicated hubs for 
the care of specific acute conditions. Cooperation between IBD 
centers is the key to improving patient outcomes.
CONCLUSIONS
The SARS-CoV-2 pandemic represents one of the 
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gastroenterologists, specifically those specializing in IBD, 
we have to put all our efforts toward protecting our patients 
during these difficult days. Empowering telemedicine, cre-
ating network strategies, and adequately counseling our pa-
tients are key measures to overcome this crisis and to create 
gold-standard strategies for improved care of IBD patients in 
the future.
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